OnKure (OKUR) CMO Agresta Receives Award & Options Repriced

What Happened

• Dr. Samuel Agresta, Chief Medical Officer of OnKure Therapeutics (OKUR), received a 50,000-share award (reported at $0.00) and was affected by a company-wide option repricing effective August 7, 2026. The filing shows derivative transactions where existing options were cancelled/disposed and replacement options were granted (18,588 and 131,396-share option blocks), consistent with the repricing.
• Per the filing, the repriced options now have an amended exercise price of $4.14 per share (the closing price on the Effective Date). The repricing applied to options with prior exercise prices ≥ $10.00. There was no change to the number of shares underlying the options, their vesting schedules, or expiration dates.

Key Details

• Transaction date: August 7, 2026; Form 4 filed August 11, 2026 (timely within required filing window).
• Award: 50,000 shares @ $0.00 reported as an acquisition.
• Option repricing: existing option blocks of 18,588 and 131,396 shares were cancelled/replaced (derivative dispositions and acquisitions reflected in the filing); new exercise price = $4.14/share.
• Retention/early-exercise premium: if a repriced option is exercised before the end of the "Retention Period" (through the earlier of Feb 7, 2028 or a Change in Control), the holder must pay a premium equal to the original exercise price per share.
• Vesting notes: the filing includes several vesting schedules for the affected options (monthly vesting schedules such as 1/48th or 1/36th per month and a tranche with 1/4 vested previously); the repricing did not change vesting (see footnotes F1–F5).
• Shares owned after the transactions: not specified in the provided filing excerpt.

Context

• These are derivative transactions reflecting an employer-initiated option repricing and a stock award — not an open-market purchase or sale. Repricing reduces the exercise price but does not increase the number of shares or accelerate vesting. The filing is procedural and does not by itself indicate insider sentiment; it documents the company’s one-time Option Repricing program effective Aug 7, 2026.